menu

How ADCs Are Transforming HER2+ Metastatic Breast Cancer: Discover the Latest Clinical Trend

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How ADCs Are Transforming HER2+ Metastatic Breast Cancer: Discover the Latest Clinical Trend

close
3 chapters
Play All
0.25 credits
15 minutes
Chapter 1
How ADCs Are Transforming HER2+ Metastatic Breast Cancer: Discover the Latest Clinical Trend
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    While HER2+ breast cancers are traditionally associated with a poor prognosis, the development of HER2-directed treatment strategies has led to substantial and durable survival improvements, even in patients with metastatic disease. Nonetheless, a percentage of these patients will not respond to certain therapies, and many may become resistant within a year of treatment.

    In this chapterized activity, Dr. Javier Cortes and Dr. Sara Hurvitz discuss optimal therapy selection based on individual patient characteristics as well as strategies to manage potential adverse events associated with current treatment options for HER2+ metastatic breast cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Javier Cortes, MD, PhD
    Head, Breast Cancer Program
    IOB Institute of Oncology
    Madrid & Barcelona
    Spain

    Consulting Fees: AstraZeneca, Athenex, Bioasis, BioInvent, Biothera Pharmaceutical, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Eisai, Ellipses, Erytech, GEMoaB, GSK, HiberCell, Kyowa Kirin, Leuko, Lilly, Merck Sharp & Dohme, Merus, Novartis, Pfizer, Polyphor, Roche, Samsung Bioepis, Seattle Genetics, Servier
    Contracted Research: Research funding to the Institution: ARIAD Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C, Queen Mary University of London, Roche
    Ownership Interest: MEDSIR

    Faculty:
    Sara A. Hurvitz, MD, FACP
    Associate Professor of Medicine
    UCLA
    Los Angeles, CA

    Contracted Research: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, Puma, Radius, Samumed, Sanofi, Seattle Genetics, Zymeworks
    Ownership Interest: NKMax (self), ROMTech, Ideal Implant (spouse)

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Demonstrate optimal therapy selection based on individual patient characteristics in the HER2-positive metastatic breast cancer setting
    • Formulate strategies to manage potential adverse events associated with current treatment options for HER2-positive metastatic breast cancer
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and other healthcare professionals treating breast cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    While HER2+ breast cancers are traditionally associated with a poor prognosis, the development of HER2-directed treatment strategies has led to substantial and durable survival improvements, even in patients with metastatic disease. Nonetheless, a percentage of these patients will not respond to certain therapies, and many may become resistant within a year of treatment.

    In this chapterized activity, Dr. Javier Cortes and Dr. Sara Hurvitz discuss optimal therapy selection based on individual patient characteristics as well as strategies to manage potential adverse events associated with current treatment options for HER2+ metastatic breast cancer.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Javier Cortes, MD, PhD
    Head, Breast Cancer Program
    IOB Institute of Oncology
    Madrid & Barcelona
    Spain

    Consulting Fees: AstraZeneca, Athenex, Bioasis, BioInvent, Biothera Pharmaceutical, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Eisai, Ellipses, Erytech, GEMoaB, GSK, HiberCell, Kyowa Kirin, Leuko, Lilly, Merck Sharp & Dohme, Merus, Novartis, Pfizer, Polyphor, Roche, Samsung Bioepis, Seattle Genetics, Servier
    Contracted Research: Research funding to the Institution: ARIAD Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma C, Queen Mary University of London, Roche
    Ownership Interest: MEDSIR

    Faculty:
    Sara A. Hurvitz, MD, FACP
    Associate Professor of Medicine
    UCLA
    Los Angeles, CA

    Contracted Research: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, Puma, Radius, Samumed, Sanofi, Seattle Genetics, Zymeworks
    Ownership Interest: NKMax (self), ROMTech, Ideal Implant (spouse)

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Demonstrate optimal therapy selection based on individual patient characteristics in the HER2-positive metastatic breast cancer setting
    • Formulate strategies to manage potential adverse events associated with current treatment options for HER2-positive metastatic breast cancer
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and other healthcare professionals treating breast cancer.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/27/21